CA2646319A1 - Methods and compositions based on shiga toxin type 1 protein - Google Patents

Methods and compositions based on shiga toxin type 1 protein Download PDF

Info

Publication number
CA2646319A1
CA2646319A1 CA002646319A CA2646319A CA2646319A1 CA 2646319 A1 CA2646319 A1 CA 2646319A1 CA 002646319 A CA002646319 A CA 002646319A CA 2646319 A CA2646319 A CA 2646319A CA 2646319 A1 CA2646319 A1 CA 2646319A1
Authority
CA
Canada
Prior art keywords
antibody
stx1
polypeptide
amino acid
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002646319A
Other languages
English (en)
French (fr)
Inventor
Angela Melton-Celsa
Michael Smith
Alison O'brien
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Henry M Jackson Foundation for Advancedment of Military Medicine Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2646319A1 publication Critical patent/CA2646319A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/24—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • C07K14/245—Escherichia (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1203—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria
    • C07K16/1228—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1203—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria
    • C07K16/1228—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • C07K16/1232—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia from Escherichia (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Mycology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
CA002646319A 2006-04-20 2007-04-20 Methods and compositions based on shiga toxin type 1 protein Abandoned CA2646319A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US79391806P 2006-04-20 2006-04-20
US60/793,918 2006-04-20
PCT/US2007/009799 WO2007124133A2 (en) 2006-04-20 2007-04-20 Methods and compositions based on shiga toxin type 1 protein

Publications (1)

Publication Number Publication Date
CA2646319A1 true CA2646319A1 (en) 2007-11-01

Family

ID=38625659

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002646319A Abandoned CA2646319A1 (en) 2006-04-20 2007-04-20 Methods and compositions based on shiga toxin type 1 protein

Country Status (7)

Country Link
US (3) US8293245B2 (cg-RX-API-DMAC7.html)
EP (2) EP2420246A1 (cg-RX-API-DMAC7.html)
JP (1) JP2009536818A (cg-RX-API-DMAC7.html)
AU (1) AU2007240614B2 (cg-RX-API-DMAC7.html)
CA (1) CA2646319A1 (cg-RX-API-DMAC7.html)
MX (1) MX2008013363A (cg-RX-API-DMAC7.html)
WO (1) WO2007124133A2 (cg-RX-API-DMAC7.html)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030170248A1 (en) * 1997-12-23 2003-09-11 Jeffrey R. Stinson Humanized monoclonal antibodies that protect against shiga toxin induced disease
EP1229045A1 (en) * 2001-02-01 2002-08-07 Institut Curie Universal carrier for targeting molecules to Gb3 receptor expressing cells
AU2007240614B2 (en) 2006-04-20 2013-09-12 The Henry M. Jackson Foundation For The Advancement Of Military Medicine Incorporated Methods and compositions based on Shiga toxin type 1 protein
US20090258010A1 (en) * 2006-05-31 2009-10-15 Thallion Pharmaceuticals, Inc. Methods, compositions, and kits for treating shiga toxin associated conditions
PE20120425A1 (es) * 2009-01-23 2012-05-03 Jackson H M Found Military Med Metodos y composiciones en base a la proteina tipo 2 de la toxina shiga
US8734811B2 (en) * 2009-04-06 2014-05-27 University Of Saskatchewan Methods and compositions for treating and preventing Shiga toxin-producing Escherichia coli infection
AU2014285024A1 (en) * 2013-07-03 2016-01-21 Roka Bioscience, Inc. Compositions, kits, and related methods for detecting and/or monitoring Shiga toxin producing Escherichia coli
CN104558167B (zh) * 2014-12-26 2017-12-26 江苏省疾病预防控制中心 检测i型志贺毒素双抗夹心法酶联免疫试剂盒及其应用
CN111902539B (zh) * 2018-02-07 2025-05-16 吉尼松公司 杂合调控元件
RU2732155C1 (ru) * 2019-09-24 2020-09-11 Открытое акционерное общество "Всероссийский научный Центр молекулярной диагностики и лечения" (ОАО ВНЦМДЛ) Гуманизированное антитело или его антигенсвязывающий фрагмент (Fab) против шига-токсинов первого и/или второго типов (варианты), композиция для лечения токсических состояний, вызванных энтерогеморрагической кишечной палочкой, содержащая указанные антитела и/или Fab

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
JPS6147500A (ja) 1984-08-15 1986-03-07 Res Dev Corp Of Japan キメラモノクロ−ナル抗体及びその製造法
EP0173494A3 (en) 1984-08-27 1987-11-25 The Board Of Trustees Of The Leland Stanford Junior University Chimeric receptors by dna splicing and expression
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
US4573986A (en) * 1984-09-17 1986-03-04 The Procter & Gamble Company Disposable waste-containment garment
JPS61134325A (ja) 1984-12-04 1986-06-21 Teijin Ltd ハイブリツド抗体遺伝子の発現方法
WO1987002671A1 (en) 1985-11-01 1987-05-07 International Genetic Engineering, Inc. Modular assembly of antibody genes, antibodies prepared thereby and use
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
JPS62292890A (ja) 1986-06-13 1987-12-19 Sanritsu Kikaku Kk 固形潤滑材
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5258498A (en) 1987-05-21 1993-11-02 Creative Biomolecules, Inc. Polypeptide linkers for production of biosynthetic proteins
US5164298A (en) * 1988-06-24 1992-11-17 Hsc Research Development Corporation Verocytotoxin receptor assay
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6657103B1 (en) 1990-01-12 2003-12-02 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
WO1992003918A1 (en) 1990-08-29 1992-03-19 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US6255458B1 (en) 1990-08-29 2001-07-03 Genpharm International High affinity human antibodies and human antibodies against digoxin
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
IE922437A1 (en) 1991-07-25 1993-01-27 Idec Pharma Corp Recombinant antibodies for human therapy
JP3939746B2 (ja) 1991-07-25 2007-07-04 バイオジェン・アイデック・インコーポレイテッド 細胞毒性ｔ−リンパ球応答の誘導
US5709860A (en) 1991-07-25 1998-01-20 Idec Pharmaceuticals Corporation Induction of cytotoxic T-lymphocyte responses
US5756096A (en) 1991-07-25 1998-05-26 Idec Pharmaceuticals Corporation Recombinant antibodies for human therapy
CA2078539C (en) * 1991-09-18 2005-08-02 Kenya Shitara Process for producing humanized chimera antibody
NZ255101A (en) 1992-07-24 1997-08-22 Cell Genesys Inc A yeast artificial chromosome (yac) vector containing an hprt minigene expressible in murine stem cells and genetically modified rodent therefor
US5747272A (en) * 1994-02-14 1998-05-05 Henry M. Jackson Foundation For The Advancement Of Military Medicine Detection of shiga-like toxins of enterohemoragic Escherichia coli
US5968894A (en) * 1994-02-22 1999-10-19 Lingwood; Clifford A. Verotoxin pharmaceutical compositions and medical treatments therewith
ATE483733T1 (de) 1995-06-14 2010-10-15 Univ California Hochaffine humane antikörper gegen tumorantigene
CA2265887A1 (en) * 1996-09-10 1998-03-19 Henry M. Jackson Foundation For The Advancement Of Military Medicine Histidine-tagged shiga toxins, toxoids, and protein fusions with such toxins and toxoids, methods for the purification and preparation thereof
WO1998020903A1 (en) * 1996-11-15 1998-05-22 Trustees Of Tufts College Humanized neutralizing antibodies against hemolytic uremic syndrome
US7910096B2 (en) * 1996-11-15 2011-03-22 Trustees Of Tufts College Human neutralizing antibodies against hemolytic uremic syndrome
US20020160005A1 (en) * 1996-11-15 2002-10-31 Trustees Of Tufts College Human neutralizing antibodies against hemolytic urmec syndrome
US20030170248A1 (en) * 1997-12-23 2003-09-11 Jeffrey R. Stinson Humanized monoclonal antibodies that protect against shiga toxin induced disease
KR100548167B1 (ko) 1998-05-20 2006-01-31 데이진 가부시키가이샤 베로톡신 ⅱ를 인식하는 인체 적응된 항체 및 그것을 생산하는 세포주
JP2002529695A (ja) * 1998-10-30 2002-09-10 フォトニック センサー システムズ 酸または塩基を検出または測定するための方法およびセンサ
US6833268B1 (en) 1999-06-10 2004-12-21 Abgenix, Inc. Transgenic animals for producing specific isotypes of human antibodies via non-cognate switch regions
EP1648501B1 (en) * 2003-07-21 2011-04-06 Intervet International BV Hybrid toxins comprising shiga-like toxin subunits fused to escherichia coli heat labile enterotoxin subunits and vaccines thereof
JP5618453B2 (ja) 2003-11-28 2014-11-05 ナショナル リサーチ カウンシル オブ カナダ 抗癌抗体およびその使用
CA2555306A1 (en) * 2004-02-06 2005-08-18 Nymox Corporation Humanized antibody
US8846058B2 (en) * 2006-02-16 2014-09-30 The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. Shiga toxoid chimeric proteins
AU2007240614B2 (en) 2006-04-20 2013-09-12 The Henry M. Jackson Foundation For The Advancement Of Military Medicine Incorporated Methods and compositions based on Shiga toxin type 1 protein
US20090258010A1 (en) * 2006-05-31 2009-10-15 Thallion Pharmaceuticals, Inc. Methods, compositions, and kits for treating shiga toxin associated conditions
WO2008080218A1 (en) 2006-12-29 2008-07-10 Osprey Pharmaceuticals Usa, Inc. Methods of selecting and producing modified toxins, conjugates containing modified toxins and uses thereof
PE20120425A1 (es) 2009-01-23 2012-05-03 Jackson H M Found Military Med Metodos y composiciones en base a la proteina tipo 2 de la toxina shiga

Also Published As

Publication number Publication date
AU2007240614A1 (en) 2007-11-01
WO2007124133A2 (en) 2007-11-01
EP2420246A1 (en) 2012-02-22
JP2009536818A (ja) 2009-10-22
US20070292426A1 (en) 2007-12-20
WO2007124133A3 (en) 2008-11-27
US20140023652A1 (en) 2014-01-23
US8293245B2 (en) 2012-10-23
AU2007240614B2 (en) 2013-09-12
US20130101591A1 (en) 2013-04-25
EP2019684A2 (en) 2009-02-04
EP2019684A4 (en) 2009-08-26
MX2008013363A (es) 2009-03-26

Similar Documents

Publication Publication Date Title
AU2010206800B2 (en) Methods and compositions based on Shiga toxin type 2 protein
US20140023652A1 (en) Methods and compositions based on shiga toxin type 1 protein
US10053503B2 (en) Monoclonal antibodies that neutralize anthrax toxins
AU2014270598B2 (en) Generation of highly potent antibodies neutralizing the LukGH (LukAB) toxin of Staphylococcus aureus
AU2013251165A1 (en) Cross-reactive Staphylococcus aureus antibody
JP2016511633A (ja) Ｍｄｒ大腸菌特異的抗体
Farshad et al. Production and characterization of monoclonal antibodies against Brucella abortus S (99) surface antigens

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued

Effective date: 20140422